Loading clinical trials...
Loading clinical trials...
A Randomised, Double Blind, Parallel, Interventional Phase IIa Proof of Concept Trial to Evaluate the Efficacy and Safety of ZYIL1 for the Treatment of Patients With Mild to Moderately Active Ulcerative Colitis Resistant or Intolerant to Oral Aminosalicylates
Conditions
Interventions
Arm1
Arm 2
Locations
1
India
ICON Hospital
Ahmedabad, Gujarat, India
Start Date
April 8, 2024
Primary Completion Date
November 22, 2024
Completion Date
November 28, 2024
Last Updated
December 20, 2024
NCT07271069
NCT06975722
NCT07185009
NCT07184996
NCT07245394
NCT07089420
Lead Sponsor
Zydus Lifesciences Limited
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions